Have a personal or library account? Click to login
A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights Cover

A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

Radiology and Oncology
Volume 57 (2023): Issue 3 (September 2023)
By: Xing Li,  Kaida Liu,  Lidong Xing and  Boris Rubinsky  
Open Access
|Sep 2023

Figures & Tables

FIGURE 1.

The process of TTFields clinical trials on typical tumor types.
The process of TTFields clinical trials on typical tumor types.

FIGURE 2.

Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide
Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide

FIGURE 3.

Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928
Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928

FIGURE 4.

Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival
Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival

FIGURE 5.

Researches on potential mechanisms of TTFields action.
Researches on potential mechanisms of TTFields action.
DOI: https://doi.org/10.2478/raon-2023-0044 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 279 - 291
Submitted on: Jul 20, 2023
Accepted on: Aug 4, 2023
Published on: Sep 4, 2023
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
tumor treating fields,
clinical applications of TTFields,
mechanisms of action of TTFields
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2023 Xing Li, Kaida Liu, Lidong Xing, Boris Rubinsky, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 57 (2023): Issue 3 (September 2023)Next article